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Are Genetic Factors Important
in Stroke Risk?
Stroke is the third commonest cause of
death and the major cause of adult
neurological disability. It is a major health
problem not only in the developed world,
but is increasing in incidence in much of
the developing world. Cerebrovascular
disease is also an important cause of
dementia and age-related cognitive de-
cline, and the commonest cause of late-
onset epilepsy. Conventional risk factors
such as high blood pressure account for a
significant proportion of stroke risk but
much risk remains unexplained, and we
do not understand why some individuals
with risk factors such as hypertension
develop stroke while others with similar
risk factor profiles remain disease free. It
has been suggested that genetic factors
may be responsible for some of this
unexplained risk, but what is the evidence
for this?
Limited data from twin studies suggests
stroke is more common in monozygotic
compared with dizygotic twins, consistent
with a role for genetic factors [1].
Considerably more data is available for
family history studies, which show a family
history of stroke is more common in
individuals with ischaemic stroke [1].
The association is stronger for younger
individuals, and those with the large artery
disease and small vessel disease subtypes of
stroke [2,3]. This association may repre-
sent genetic predisposition, but could also
be explained by shared environmental
factors. More robust data come from
studying intermediate phenotypes of
stroke. These are markers of disease,
usually detected on imaging, which repre-
sent intermediate stages of disease pathol-
ogy leading to stroke. Both twin and family
studies have shown that MRI white matter
hyperintensities, which usually represent
small vessel disease [4], are the most
heritable cerebrovascular phenotype, with
a heritability (proportion of variation
explained by genetic factors) estimated to
be between 55% and 71% [5–7]. Carotid
artery intima-media thickness, measured
by ultrasound and believed to represent
early stages of atherosclerosis and there-
fore relate to large artery stroke [8,9], has
been estimated to have a heritability of
30% to 68% [10–13].
Why Should We Identify Genes
for Stroke?
A small proportion of ischaemic stroke is
monogenic [14]. A mutation in a specific
gene results in disease, and most individuals
with the abnormality are likely to develop
stroke at some stage in their life. For these
diseases identifying the underlying muta-
tion allows diagnosis, prognostic informa-
tion, specific treatments in some cases, and
enables counselling of other family mem-
bers. However, the vast majority of stroke
appears to be ‘‘polygenic’’; multiple genes,
each likely to confer a small risk, interact
with environmental risk factors to result in
disease [15]. Identifying these underlying
genetic risk factors may allowimproved risk
profiling, although as each genetic variant
is likely to confer only a small risk, any
useful risk prediction is likely to require a
combination of multiple markers. Genetic
testing for other polygenic diseases has
already been developed, and indeed some
gene tests for stroke are already marketed.
However, their clinical relevance has been
debated; most panels of genetic markers
available explain only a small portion of
total ‘‘geneticrisk’’[16].Furthermore,their
use has been questioned when clinicians
already have difficulty treating known risk
factors such as hypertension, which make a
stronger contribution to risk, and concern
has been expressed over the psychological
consequences of testing. Perhaps more
importantly, discovering genetic variants
conferring increased stroke risk may allow
new pathways involved in the pathogenesis
of stroke to be identified and new treat-
ments to be developed. This approach is
just beginning to bear fruit in other
‘‘complex’’ diseases involving interactions
between multiple genes and environment,
such as macular degeneration and Crohn’s
disease [17,18].
How Can We Identify Genes for
Stroke?
Linkagetechniques havebeensuccessfully
used to identify a number of genes causing
monogenic stroke. This relies on identifying
associations between chromosomal markers
and disease phenotype within families.
Linkage is good at identifying genes confer-
ring greatly increased risk, but has been less
successful in common polygenic complex
disease such as stroke. There was excitement
when this approach identified the STRK1
gene in the Icelandic population as phos-
phodiesterase 4D [19], but this could not be
replicated in other European populations
[20].
Until recently the mainstay of investi-
gating stroke genetics was the candidate
gene method. Genetic variants (usually
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are identified in a ‘‘candidate’’ gene that is
hypothesised to be involved in stroke risk.
The frequency of the SNP is compared in
a group of stroke patients compared with
controls. Many hundreds of such studies
have been carried out in stroke with
largely disappointing results [21]. This
picture is common to many other complex
diseases, and the reasons for lack of success
have been explored in detail [21]. Impor-
tant factors include small sample sizes,
failure to phenotype cases accurately, and
failure to replicate positive associations,
combined with publication bias resulting
in preferential publication of positive
associations. A major problem with the
candidate gene method is that associations
can be identified only in genes already
discovered and implicated in the disease.
Completely novel genes involved in dis-
ease risk cannot be identified.
The Genome-Wide Association
Study (GWAS) Approach
Recently the field of complex genetics
has been revolutionised by the genome-
Summary Points
N Epidemiological studies suggest genetic predisposition is important in stroke
risk.
N Monogenic conditions are important for the individual patient but do not
account for much population attributable risk. An increasing number of such
conditions are being described, particularly for the small vessel disease stroke
subtype.
N The candidate genes approach has proved disappointing in identifying genes
contributing to the risk of multifactorial or polygenic stroke. This is a situation
shared with other complex diseases.
N Recently the GWAS (genome-wide association study) approach has identified
genetic loci for many other cardiovascular diseases such as coronary heart
disease, diabetes, and hypertension, and is just being applied to stroke. Some
novel genetic variants initially associated with other cardiovascular diseases
have recently been identified as risk factors in stroke populations.
Figure 1. Published associations between chromosomal loci and many diseases which have been identified by genome-wide
associations up to June 2009. A significance level of p,5610
28 has been used to determine whether associations are significant. As can be seen
a large number of associations have been identified with many common diseases. Credit: Darryl Leja and Teri Manolio; available from http://www.
genome.gov/gwastudies. Accessed 25 September 2009.
doi:10.1371/journal.pmed.1000225.g001
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[22]. This allows up to 1 million SNPs
spanning the whole genome to be geno-
typed in a single individual. Using a case
control methodology, and rigorous statisti-
cal methods to account for the multiple
comparisons made, associations between
completely unexpected chromosomal loci
and disease can be identified. With this
approach, combined with much larger
study sizes involving thousands of patients
and rigorous replication of positive results,
over 600 new genetic loci have been
discovered predisposing to other complex
disorders such as diabetes and myocardial
infarction (Figure 1) [23]. An early success
was in age-related macular degeneration,
which, like stroke, is primarily a disease of
the elderly in which cardiovascular risk
factors increase risk [24]. Robust and
replicable associations were identified with
complement factor H, and this has allowed
new treatment approaches to be developed.
Novel genetic association have now been
reported in many cardiovascular diseases
including myocardial infarction, diabetes,
obesity, hypertension, and hyperlipidaemia
[23]. An important message from these
studies is that most genetic variants discov-
ered using this approach individually
account for only a small increase in risk,
with odds ratios usually between 1.1 and
1.3. This means large sample sizes are
required to identify such variants.
The GWAS Approach in Stroke
Stroke genetics has lagged behind that of
many other complex diseases, and the
GWAS approach is only just beginning to
be applied. An early study in 500 individuals
found no definite associations, but we now
appreciate this was underpowered [25].
Larger studies are currently taking place in
the UK (as part of the Wellcome Case
Control Consortium 2), the US, Australia,
and other countries. As yet most data, and
most current studies, are from white popu-
lations. Other complex diseases have taught
us that we may need very large sample sizes
to identify genetic variants. For example, in
hypertension, initial studies in a few thou-
sand cases were disappointing. More recent-
ly meta-analysis of over 80,000 cases
identified eight novel genetic loci [26]. The
importance of robust replication prior to
publication was demonstrated by the recent
high-profile publication of a novel Chromo-
some 12 locus associated with stroke iden-
tified on GWAS [27], which unfortunately
could not be replicated in a sample of over
10,000 individuals, although differences in
study designs—the original study was based
on prospective cohorts and the replication
was cross-sectional—could potentially ac-
count for some of the discrepancy [28]. The
lack of success in stroke so far is likely to
reflect the relatively small sample sizes
studied to date, but other issues may also
be important. For example, the GWAS
approach relies on the existence of common
variants, each of which confer risk. It is less
good at detecting rare variants which could
also confer increased risk.
Some novel genetic variants initially
associated with other cardiovascular dis-
eases have recently been identified as risk
factors in stroke populations. A Chromo-
some 9 variant associated with myocardial
infarction and coronary artery disease [29]
was found to also be associated with stroke
across multiple populations, but this asso-
ciation was due to an association with
large artery stroke, and no association was
found with other stroke subtypes [30].
Two other variants identified as risk
factors for atrial fibrillation have also been
associated with stroke; here the association
was primarily with cardioembolic stroke
[31,32]. These findings emphasise that
genetic risk factors may predispose to
specific subtypes of stroke. Therefore,
identifying such risk factors will depend
on rigorous stroke phenotyping and large
numbers of cases with each stroke subtype.
Monogenic Stroke Disorders
A large number of rare monogenic
disorders can cause stroke (Table 1) Some
of these result in stroke as part of a
systemic disorder, while others produce a
clinical phenotype limited to the central
nervous system [14]. Progress has been
particularly exciting in cerebral small
vessel disease. This causes lacunar stroke,
which accounts for about 20% of ischae-
mic stroke, and is the most common cause
of vascular dementia. The most common
monogenic form of small vessel disease is
CADASIL (cerebral autosomal dominant
arteriopathy with subcortical infarcts and
leukoencephalopathy), which results from
mutations in the NOTCH3 gene [33]. A
striking feature of CADASIL is that, even
within families, disease severity is highly
variable. This variation is not accounted
for by the site of the disease mutation.
Confluent white matter hyperintensity
called leukoaraiosis, and best seen on
MRI, is a prominent feature in CADASIL.
A recent study measuring leukoaraiosis
volume demonstrated that the variability
in leukoariosis volume between different
CADASIL carriers has a strong genetic
predisposition, with a heritability as high
Table 1. Monogenic or single gene disorders causing stroke, classified according to
the each one’s stroke subtype.
Stroke Subtype Specific Monogenic Disease
Small vessel disease CADASIL
CARASIL
Cerebrovascular retinopathy and HERNS
COL4A1 small vessel arteriopathy with haemorrhage
Large artery atherosclerosis and other
arteriopathies
Familial hyperlipidaemias
Moya-Moya disease
Pseudoxanthoma elasticum
Neurofibromatosis type I
Large artery disease—dissection Ehlers-Danlos syndrome type IV
Marfan syndrome
Fibromuscular dysplasia
Disorders affecting both small and
large arteries
Fabry disease
Homocysteinuria
Sickle cell disease
Cardioembolism Familial cardiomyopathies
Familial arrhythmias
Hereditary haemorrhagic telangiectasia
Prothrombotic disorders
Mitochondrial disorders MELAS
HERNS, hereditary endotheliopathy with retinopathy, nephropathy, and stroke; MELAS, Mitochondrial
myopathy, encephalopathy, lactic acidosis, and stroke.
doi:10.1371/journal.pmed.1000225.t001
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possibility that other genes modulate the
damage caused by the NOTCH3 mutation
to modify the disease phenotype. GWAS
studies are currently being planned to try
to identify these modifying genes. Whether
such genes modify only leukoaraiosis
severity in CADASIL, or whether they
could also play an important role in
modifying white matter damage in re-
sponse to other more common risk factors
such as hypertension, remains to be
determined. Similar GWAS studies are
being carried out using the intermediate
phenotype of white matter hyperintensity
lesion volume both in normal populations
and in populations with stroke and stroke
risk factors. It will be interesting to
compare the results of the studies in
different populations.
Genes causing a number of rarer mono-
genic forms of small vessel disease have
recently been identified. CARASIL (cere-
bral autosomal recessive arteriopathy with
subcortical infarcts and leukoencephalopa-
thy), which causes lacunar stroke, leukoar-
aiosis, and early onset vascular dementia,
has been shown to results from mutations in
t h eH t r As e r i n ep r o t e a s e1( HTRA1) gene,
which is involved in TGF-b signalling [35].
Autosomal dominant retinal vasculopathy
with cerebral leukodystrophy is a microvas-
cular endotheliopathy presenting with visual
loss, stroke, and dementia with onset in
middle age.C-terminal frameshiftmutations
in TREX1, which encodes a DNA-specific39
to 59 exonuclease ubiquitously expressed in
mammalian cells were identified [36]. These
truncated proteins retain exonuclease activ-
ity but lose normal perinuclear localization.
COL4A1, a gene encoding the type IV
collagen alpha1 chain, has been found to
be involved in families with autosomal-
dominant porencephaly and infantile hemi-
paresis [37]. Patients have been reported to
present with adult-onset white matter isch-
aemic changes consistent with small vessel
disease with microbleeds in the absence of
infantile hemiparesis or intracerebral haem-
orrhage [38]. Fabry disease is an X-linked
recessive lysosomal storage disease resulting
from deficient alpha-galactosidase which
causes organ failure in multiple beds
including the brain. Stroke may result from
a number of mechanisms including cerebral
small vessel disease, and confluent white
matter ischaemic changes are seen on MRI.
It was reported be an important cause of
young-onset cryptogenic ischemic stroke,
accounting for 4.9% of male cases and
2.4% of female cases, although further
studies are required to confirm this [39].
Therefore multiple different gene defects
resulting in disruption of multiple different
pathways can result in the a similar clinical
phenotypes of cerebral small vessel disease.
Conclusions
In summary, genetic factors appear to
be important in stroke risk, although we
do not really know how important.
Candidate gene studies have been largely
disappointing but with GWAS technology
we may well be at the dawn of a new era
in stroke genetics. Future technological
advances such as copy number variant
determination and, whole genome se-
quencing are also likely to be important;
the latter will allow rare variants associat-
ed with disease to be identified. Studies to
date have emphasised the importance of
careful phenotyping or stroke subtyping,
and the experience of other complex
diseases has taught us that we need large
sample studies and rigorous replication of
results.
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